How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
Seqens CDMO North America Honored for Service Excellence for 6th Straight Year
Continuous Manufacturing is Gaining Steam, but Batch Processing Continues to be a Proven Alternative
PCI Synthesis’ Director of Analytical Services Dedicates Lab Expansion of Outsourcing Partner: Diace...
Does the CDMO Manage Multiple API Development Projects Well?
5 Points to Consider when Evaluating your CMO's Analytical Capabilities
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...